Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921290 | 0.94 | HRH3 (0.50) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL9921270 | 0.94 | HRH3 (0.50) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL14207965 | 0.89 | HRH3 (0.45) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL23206108 | 0.89 | HRH3 (0.45) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL23205030 | 0.89 | HRH3 (0.45) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL30603861 | 0.84 | CXCR4 (0.57) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL23828669 | 0.84 | CXCR4 (0.57) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL13891348 | 0.82 | HRH3 (0.50) | HRH3KCNH2 | |
| SCHEMBL16418015 | 0.82 | HRH3 (0.50) | HRH3KCNH2 | |
| SCHEMBL9921291 | 0.82 | HRH3 (0.50) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | SCN1A 1027/4885SCN2A 1004/4885SCN3A 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.